Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MTOR | P42345 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.67 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.67 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.67 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | DUT | P33316 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL18249683 | 0.96 | P2RY2 (0.71) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL9674279 | 0.92 | P2RY2 (0.61) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL7196447 | 0.91 | LMNA (0.79) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxribtimine SCHEMBL29124320 | 0.90 | P2RY2 (0.60) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL600535 | 0.90 | LMNA (0.80) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL17371752 | 0.90 | LMNA (0.80) | LMNAMTORTHRBMDM2NCOA1 | |
| Uridine SCHEMBL2563446 | 0.88 | SLC28A1 (0.78) | LMNAP2RY2P2RY4P2RY6SLC28A1 | |
| Doxribtimine SCHEMBL787714 | 0.87 | LMNA (0.62) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL4468985 | 0.87 | LMNA (0.65) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxribtimine SCHEMBL6518312 | 0.87 | LMNA (0.62) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622572-B1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3231445-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3222294-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2415486-B1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2415486-A2 | Conjugates and compositions for cellular delivery | Sirna Therapeutics, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7964578-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | CHEN TONGQIAN | 2011-05-26 | — | — | US | disclosed |
| US-7833992-B2 | biological conjugates used for drug delivery; side effect reduction | MERCK SHARPE & DOHME (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090264636-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1572067-A4 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1622572-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1572067-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | ALB, PHAX, HEXA | LMNA 1239/4885MTOR 4716/4885THRB 303/4885 |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | ALB, FUT5, RNGTT | LMNA 1219/4885MTOR 4775/4885THRB 426/4885 |
| US-20090264636-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | ALB, PHAX, HEXA | LMNA 1239/4885MTOR 4716/4885THRB 303/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | LMNA 1747/4885MTOR 4762/4885THRB 205/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | LMNA 1747/4885MTOR 4762/4885THRB 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.